AU2013291970B2 - Baclofen and acamprosate based therapy of Macular Degeneration disorders - Google Patents

Baclofen and acamprosate based therapy of Macular Degeneration disorders Download PDF

Info

Publication number
AU2013291970B2
AU2013291970B2 AU2013291970A AU2013291970A AU2013291970B2 AU 2013291970 B2 AU2013291970 B2 AU 2013291970B2 AU 2013291970 A AU2013291970 A AU 2013291970A AU 2013291970 A AU2013291970 A AU 2013291970A AU 2013291970 B2 AU2013291970 B2 AU 2013291970B2
Authority
AU
Australia
Prior art keywords
baclofen
acamprosate
macular degeneration
amd
combination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2013291970A
Other languages
English (en)
Other versions
AU2013291970A1 (en
Inventor
Ilya Chumakov
Daniel Cohen
Serguei Nabirochkin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharnext SA
Original Assignee
Pharnext SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharnext SA filed Critical Pharnext SA
Publication of AU2013291970A1 publication Critical patent/AU2013291970A1/en
Application granted granted Critical
Publication of AU2013291970B2 publication Critical patent/AU2013291970B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
AU2013291970A 2012-07-18 2013-07-18 Baclofen and acamprosate based therapy of Macular Degeneration disorders Ceased AU2013291970B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261672893P 2012-07-18 2012-07-18
US61/672,893 2012-07-18
PCT/EP2013/065209 WO2014013025A1 (en) 2012-07-18 2013-07-18 Baclofen and acamprosate based therapy of macular degeneration disorders

Publications (2)

Publication Number Publication Date
AU2013291970A1 AU2013291970A1 (en) 2015-02-19
AU2013291970B2 true AU2013291970B2 (en) 2017-09-28

Family

ID=48794112

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2013291970A Ceased AU2013291970B2 (en) 2012-07-18 2013-07-18 Baclofen and acamprosate based therapy of Macular Degeneration disorders

Country Status (17)

Country Link
US (1) US9545389B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (1) EP2874617B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JP6271539B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (1) KR20150058159A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN (1) CN104780917B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU2013291970B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR (1) BR112015001090A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA2879114A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EA (1) EA029157B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (1) ES2729208T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IL (1) IL236737B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IN (1) IN2015DN00820A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MX (1) MX364232B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NZ (1) NZ704280A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SG (1) SG11201500309VA (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO2014013025A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ZA (1) ZA201500663B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2727587A1 (en) 2012-10-30 2014-05-07 Pharnext Compositions, methods and uses for the treatment of diabetes and related conditions by controlling blood glucose level
WO2015063140A1 (en) * 2013-10-30 2015-05-07 Pharnext Compositions, methods and uses for the treatment of diabetes and related conditions by controlling blood glucose level
CN106456583B (zh) 2014-02-11 2020-04-07 法奈克斯公司 用于治疗神经障碍的巴氯芬、阿坎酸和中链甘油三酯的组合

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005027950A1 (en) * 2003-09-12 2005-03-31 Ray And Terry's Health Products, Inc. Eye nutritional supplement
WO2009004082A2 (en) * 2007-07-05 2009-01-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Anticonvulsive pharmaceutical compositions
WO2010089355A1 (en) * 2009-02-04 2010-08-12 INSERM (Institut National de la Santé et de la Recherche Médicale) Taurine or taurine-like substances for the prevention and treatment of a disease associated with retinal ganglion cell degeneration
WO2012117076A2 (en) * 2011-03-01 2012-09-07 Pharnext Baclofen and acamprosate based therapy of neurogical disorders

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6927036B2 (en) 2002-02-19 2005-08-09 Xero Port, Inc. Methods for synthesis of prodrugs from 1-acyl-alkyl derivatives and compositions thereof
MXPA06001876A (es) 2003-08-20 2006-05-17 Xenoport Inc Prodrogas de aciloxialquil carbamato, metodos de sintesis y uso.
EP2371815A1 (en) 2003-12-30 2011-10-05 XenoPort, Inc. Sythesis of acyloxyalkyl carbamate prodrugs and intermediates thereof
TWI369982B (en) 2007-01-11 2012-08-11 Xenoport Inc Sustained release oral dosage forms of a prodrug of r-baclofen and methods of treatment
US20090069419A1 (en) 2007-09-07 2009-03-12 Bernd Jandeleit Masked carboxylate neopentyl sulfonyl ester cyclization release prodrugs of acamprosate, compositions thereof, and methods of use
WO2009033079A1 (en) 2007-09-07 2009-03-12 Xenoport, Inc. Externally masked neopentyl sulfonyl ester cyclization release prodrugs of acamprosate, compositions thereof, and methods of use
WO2009052191A1 (en) 2007-10-15 2009-04-23 Xenoport, Inc. Internally masked neopentyl sulfonyl ester cyclization release prodrugs of acamprosate, compositions thereof, and methods of use
WO2009061934A1 (en) 2007-11-06 2009-05-14 Xenoport, Inc. Use of prodrugs of gaba b agonists for treating neuropathic and musculoskeletal pain
WO2009096985A1 (en) 2008-02-01 2009-08-06 Xenoport, Inc. Sustained release particulate oral dosage forms of (r)-baclofen prodrugs and methods of treatment
US20100137442A2 (en) 2008-02-01 2010-06-03 Xenoport, Inc. Sustained Release Particulate Oral Dosage Forms of (R)-Baclofen and Methods of Treatment
EP2403486A1 (en) * 2009-03-03 2012-01-11 XenoPort, Inc. Sustained release oral dosage forms of an r-baclofen prodrug
US8344028B2 (en) 2009-04-17 2013-01-01 Xenoport, Inc. Gamma-amino-butyric acid derivatives as GABAB receptor ligands

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005027950A1 (en) * 2003-09-12 2005-03-31 Ray And Terry's Health Products, Inc. Eye nutritional supplement
WO2009004082A2 (en) * 2007-07-05 2009-01-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Anticonvulsive pharmaceutical compositions
WO2010089355A1 (en) * 2009-02-04 2010-08-12 INSERM (Institut National de la Santé et de la Recherche Médicale) Taurine or taurine-like substances for the prevention and treatment of a disease associated with retinal ganglion cell degeneration
US20120027723A1 (en) * 2009-02-04 2012-02-02 Serge Picaud Taurine or taurine-like substances for the prevention and treatment of a disease associated with retinal ganglion cell degeneration
WO2012117076A2 (en) * 2011-03-01 2012-09-07 Pharnext Baclofen and acamprosate based therapy of neurogical disorders

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BANSAL R ET AL, "What is new in the management of age-related macular degeneration?", JOURNAL INTERNATIONAL MEDICAL SCIENCES ACADEMY (2010), Vol. 23, No. 3, pages 169 - 175 *

Also Published As

Publication number Publication date
EA029157B1 (ru) 2018-02-28
IL236737A0 (en) 2015-02-26
NZ704280A (en) 2017-06-30
MX364232B (es) 2019-04-16
WO2014013025A1 (en) 2014-01-23
KR20150058159A (ko) 2015-05-28
ZA201500663B (en) 2016-10-26
CN104780917B (zh) 2017-09-08
JP6271539B2 (ja) 2018-01-31
BR112015001090A2 (pt) 2017-06-27
ES2729208T3 (es) 2019-10-30
EP2874617B1 (en) 2019-02-27
US9545389B2 (en) 2017-01-17
MX2015000777A (es) 2015-10-14
CA2879114A1 (en) 2014-01-23
EA201500143A1 (ru) 2015-05-29
HK1209335A1 (en) 2016-04-01
SG11201500309VA (en) 2015-02-27
JP2015522601A (ja) 2015-08-06
US20150238452A1 (en) 2015-08-27
CN104780917A (zh) 2015-07-15
AU2013291970A1 (en) 2015-02-19
EP2874617A1 (en) 2015-05-27
IL236737B (en) 2018-12-31
IN2015DN00820A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2015-06-12

Similar Documents

Publication Publication Date Title
JP6416328B2 (ja) 筋萎縮性側索硬化症の治療のための新規組成物
US10434109B2 (en) Compositions for treating neurological disorders
KR102014883B1 (ko) 근위축성 측삭 경화증 치료용 신규 조성물
US10004744B2 (en) Therapeutic approaches for treating Parkinson's disease
AU2013291970B2 (en) Baclofen and acamprosate based therapy of Macular Degeneration disorders
US10799499B2 (en) Combinatorial therapies of neurological disorders
HK1209335B (en) Baclofen and acamprosate based therapy of macular degeneration disorders
EP3348261B1 (en) New compositions comprising baclofen, acamprosate and riluzole
US10736876B2 (en) Idalopirdine-based combinatorial therapies of Alzheimer's disease
AU2018201400A1 (en) New compositions for treating amyotrophic lateral sclerosis
EP3411025A1 (en) Novel combinatorial therapies of neurological disorders

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired